How GLP-1 analogs are reshaping diabetes care and obesity treatment and unlocking potential in cardiovascular, inflammatory, ...

GLP-1 receptor agonists and SGLT2 inhibitors are associated with a lower risk of dementia, suggesting these drugs may have a ...

GLP-1RA use was associated with lower all-cause mortality and hospitalizations among patients with T2D and comorbid atrial fibrillation.

GLP-1 receptor agonists were associated with improved survival and reduced graft loss among kidney transplant recipients with type 2 diabetes.

In a plenary session at the annual American Academy of Neurology meeting, Paul Edison, MD, PhD, of Imperial College London in ...

For patients with diabetes, semaglutide use is associated with an increased risk for nonarteritic anterior ischemic optic ...

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention for their effectiveness against weight gain, high blood sugar, and even ...

The study findings suggest a possible link between semaglutide use and an increased risk of NAION in patients with diabetes.

The two market leaders are targeting new obesity alternatives in their pipelines with an eye toward a triple threat.

GLP-1 receptor agonist prescriptions increased significantly during study period across all categories of BMI, in dose-response manner.

By Dr. Sanchari Sinha Dutta, Ph.D.Using real-world data from over 300,000 cases, scientists uncovered a significant link ...